Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2015 | The importance of targeting proliferating and quiescent cells in CLL

Peter Hillmen • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, discusses the importance of targeting proliferanting and quiescent chronic lymphocytic leukemia (CLL) cells.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

More from Peter Hillmen

Key updates from the interim analysis of the FLAIR trial 1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
CLL trial updates from EHA 2022 1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL 1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
The role of MRD in decision-making in CLL 1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals